Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)-Reference-Cited by-同舟云学术

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

Published:2017-07-28 Issue:11 Volume:31 Page:2523-2525
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Bug G,Burchert A,Wagner E-M,Kröger N,Berg T,Güller S,Metzelder S K,Wolf A,Hünecke S,Bader P,Schetelig J,Serve H,Ottmann O G

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2017242.pdf

Reference15 articles.

1. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006; 12: 4628–4635.

2. DeAngelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia 2013; 27: 1628–1636.

3. Falkenberg KJ, Johnstone RW . Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014; 13: 673–691.

4. West AC, Johnstone RW . New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014; 124: 30–39.

5. Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007; 13: 1299–1307.

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia;Cancers;2024-05-26

2. Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients;Blood Cancer Journal;2024-05-02

3. Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect;Frontiers in Immunology;2024-03-20

4. Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia - an EBMT registry analysis of 1540 patients;2024-03-05

5. Delayed Transfer of Immune Cells or the Art of Donor Lymphocyte Infusion (DLI) 2.0;The EBMT Handbook;2024